Fig. 01 -

Title Slide

Fig. 02 -

Learning Objectives

Fig. 03 -

Oral Anticoagulants

Fig. 04 -

Adoption of DOACs

Fig. 05 -

Parenteral Anticoagulants

Fig. 06 -

Coagulation Cascade

Fig. 07 -

Site of Action

Fig. 08 -

Monitoring Methods

Fig. 09 -

Factor X Assays

Fig. 10 -

Chromogenetic

Fig. 11 -

Monitoring

Fig. 12 -

Unfractionated Heparin

Fig. 13 -

Methods of Monitoring

Fig. 14 -

aPTT

Fig. 15 -

Disadvantages

Fig. 16 -

Therapeutic Range

Fig. 17 -

Advantages

Fig. 18 -

Advantages (Cont.)

Fig. 19 -

Progression

Fig. 20 -

Anti-Xa vs. aPTT

Fig. 21 -

Practical Issues

Fig. 22 -

Full-dose UFH

Fig. 23 -

Baseline Monitoring

Fig. 24 -

Prophylactic UFH Monitoring

Fig. 25 -

Low-molecular Weight Heparins

Fig. 26 -

LMWH Anti-Xa Monitoring

Fig. 27 -

Direct Oral Anticoagulants

Fig. 28 -

Advantages of DOACs

Fig. 29 -

Disadvantages of DOACs

Fig. 30 -

Monitoring Effects

Fig. 31 -

Dabigatran

Fig. 32 -

Dabigatran Example

Fig. 33 -

Factor Xa Inhibitor

Fig. 34 -

Rivaroxaban Monitoring

Fig. 35 -

Rivaroxaban Example

Fig. 36 -

Apixaban Monitoring Example

Fig. 37 -

Monitoring of Anticoagulants 1

Fig. 38 -

Monitoring of Anticoagulants 2

Fig. 39 -

Monitoring of Anticoagulants 3

Fig. 40 -

Conclusions

Fig. 41 -

Conclusions (Cont.)

Fig. 42 -

Thank You